In the last trading session, 0.32 million shares of the IGM Biosciences Inc (NASDAQ:IGMS) were traded, and its beta was 0.10. Most recently the company’s share price was $1.77, and it changed around -$0.06 or -3.28% from the last close, which brings the market valuation of the company to $105.25M. IGMS currently trades at a discount to its 52-week high of $22.50, offering almost -1171.19% off that amount. The share price’s 52-week low was $1.59, which indicates that the current value has risen by an impressive 10.17% since then. We note from IGM Biosciences Inc’s average daily trading volume that its 10-day average is 1.3 million shares, with the 3-month average coming to 406.11K.
IGM Biosciences Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.20. If we narrow it down even further, the data shows that 1 out of 18 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 10 recommended IGMS as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight. IGM Biosciences Inc is expected to report earnings per share of -0.77 for the current quarter.
IGM Biosciences Inc (NASDAQ:IGMS) trade information
Instantly IGMS has showed a red trend with a performance of -3.28% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.1199 on recent trading dayincreased the stock’s daily price by 16.51%. The company’s shares are currently down -71.03% year-to-date, but still down -15.31% over the last five days. On the other hand, IGM Biosciences Inc (NASDAQ:IGMS) is -76.08% down in the 30-day period. We can see from the shorts that 2.51 million shares have been sold at a short interest cover period of 10.72 day(s).
The consensus price target as assigned by Wall Street analysts is $16.5, which translates to bulls needing to increase their stock price by 89.27% from its current value. Analyst projections state that IGMS is forecast to be at a low of $1.5 and a high of $25.
IGM Biosciences Inc (IGMS) estimates and forecasts
IGM Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -83.47 percent over the past six months and at a 28.87% annual growth rate that is well above the industry average of 16.50%. The year-over-year growth rate is expected to be 23.34%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 366.67k in revenue for the current quarter. 3 analysts expect IGM Biosciences Inc to make 2.49M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 651k and 497k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -43.68%. Forecasts for the next quarter put sales growth at 400.47%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.65%.
IGMS Dividends
IGM Biosciences Inc’s next quarterly earnings report is expected to be released in February.
IGM Biosciences Inc (NASDAQ:IGMS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 34.95% of IGM Biosciences Inc shares, and 64.03% of them are in the hands of institutional investors. The stock currently has a share float of 98.42%. IGM Biosciences Inc stock is held by 120.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 6.8042% of the shares, which is about 4.09 million shares worth $28.1 million.
PRICE T ROWE ASSOCIATES INC /MD/, with 6.7789% or 4.08 million shares worth $28.0 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
